Tempus AI, Inc., a technology company leading the adoption of AI to advance precision medicine and patient care, announced the launch of the Tempus Advisory Board. The Tempus Advisory Board is a vital resource for the company in maintaining high standards and ensuring that the strategy and offerings continue to be grounded in expert knowledge from outside the organization. This group of engaged medical professionals is providing guidance, expertise and strategic advice to Tempus on matters related to research, product development, and clinical utility across the various aspects of the company’s AI-enabled platform.
“Since the beginning, our belief has been that clinical need and strong science must drive our work,” said Ezra Cohen, MD, Chief Medical Officer, Oncology at Tempus. “In that vein, we have formed the Tempus Advisory Board which solidifies this intent and overall mission. We are thrilled to gather this group of internationally renowned, experienced, and passionate physician leaders to support and guide our scientific and medical direction across the company, and we look forward to expanding the board as we continue to grow and evolve.”
Also Read: GeneDx to Buy Fabric Genomics for Global AI Testing Push
This group features the following advisors:
- David Carbone, MD, PhD: Dr. Carbone is a Professor of Medical Oncology, Director of the James Thoracic Oncology Center at the Ohio State University Medical Center.
- Babar Bashir, MD, MS, FACP: Dr. Bashir is an Associate Professor with a primary appointment in the Department of Medical Oncology, Division of Solid Tumors, and a secondary appointment in the Department of Pharmacology, Physiology, & Cancer Biology at Thomas Jefferson University.
- Amy Cummings, MD, PhD: Dr. Cummings is an assistant professor in the division of hematology/oncology at the University of California Los Angeles.
- Tapan M. Kadia, MD: Dr. Kadia is a Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center and serves as Co-leader of the sections of AML and developmental therapeutics.
- Marc R. Matrana, MD: Dr. Matrana is an Endowed Professor and System Director of Precision Medicine at Ochsner MD Anderson Cancer Center. He also holds a Full Professorship at the University of Queensland. His medical oncology practice focuses on cancers of the genitourinary tract.
- Robert McWilliams, MD, MSc, MSHA: Dr. McWilliams is a consultant and Professor of Oncology at Mayo Clinic as well as Deputy Director of the Cancer Practice at the Mayo Clinic Comprehensive Cancer Center.
- Tara Mitchell, MD: Dr. Mitchell is the Section Chief, Melanoma and Sarcoma, Hematology Oncology and Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania.
- Nicholas Mitsiades, MD, PhD: Dr. Mitsiades is the Albert Holmes Rowe Chair of Genetics Ill Professor of Medicine and Associate Director for Translational Research at the UC Davis Comprehensive Cancer Center.
- Ben Park, MD, PhD: Dr. Park is the Director of the Vanderbilt-Ingram Cancer Center. Dr. Park is also a Professor of Medicine in the Department of Medicine’s Division of Hematology and Oncology.
- B. J. Rimel, MD: Dr. Rimel is an Associate Professor of Obstetrics & Gynecology at Cedars-Sinai and the Medical Director of Cancer Clinical Trials Office at Cedars-Sinai Cancer.
- Mothaffar Rimawi, MD: Dr. Rimawi is the Executive Medical Director of the Dan L Duncan Comprehensive Cancer Center.
- Assuntina G. Sacco, MD: Dr. Sacco is a Professor of Internal Medicine, Division of Hematology-Oncology, and Co-Director of the Hanna and Mark Gleiberman Head and Neck Center of Excellence at UC San Diego Health Moores Cancer Center.
- Alexander Spira, MD, PhD: Dr. Spira is the Co-Director of the Virginia Cancer Specialists Research Institute, CEO and Director of NEXT Oncology Virginia, Chair of the Research Advisory Board of USOncology, and Clinical Assistant Professor at Johns Hopkins.
Source: Businesswire